Andere Sprachen Eli Lilly and Company

Aktien

858560

US5324571083

LLY

Pharmazeutika

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 23.06.2025			Nachbörslich 02:00:00
770,64 ^USD	+1,04 %		774,50	+0,50 %

23.06.	Amgens experimentelles Abnehm-Medikament MariTide erfordert niedrigere Anfangsdosis zur Begrenzung von Nebenwirkungen	RE
23.06.	Wall Street steigt: Zinssenkungshoffnungen überwiegen Nahost-Turbulenzen	RE

Andere Sprachen

Amgen experimental weight-loss drug needs lower dose to limit side effects	23.06.
Wall St rallies as rate cut hopes outweigh Middle East turmoil	23.06.
Low start dose of Amgen experimental weight-loss drug limits side effects	23.06.
Wall St climbs after Fed's Bowman hints at rate cut; Tesla jumps	23.06.
Eli Lilly Keeps Quarterly Dividend at $1.50 a Share, Payable Sept. 10 to Shareholders of Record as of Aug. 15	23.06.
Lilly declares third-quarter 2025 dividend	23.06.
Wall St indexes climb as oil dips; Tesla surges	23.06.
Eli Lilly and Company Declares Dividend for the Third Quarter of 2025, Payable on September 10, 2025	23.06.
Global markets live: Tesla, Eli Lilly, BNY Mellon, Novo Nordisk, Stellantis…	23.06.
Novo Nordisk shares fall as obesity pipeline faces investor scrutiny	23.06.
USA-Les valeurs à suivre à Wall Street (actualisé)	23.06.
ELI LILLY : Jefferies still a buyer	23.06.
Apple, Eli Lilly, Tesla... Les valeurs à suivre aujourd'hui à Wall Street -	23.06.
Eli Lilly : des données positifs pour l'insuline Efsitora	23.06.
Eli Lilly: positive results for oral orforglipron	23.06.
Lilly's Oral GLP-1 Orforglipron Meets Key Goals in Phase 3 Diabetes Study	23.06.
Eli Lilly: positive results for efsitora alfa insulin	23.06.
Eli Lilly Says Investigational Once-Weekly Insulin Meets Primary Endpoint in Phase 3 Trials	23.06.
PRESS DIGEST-British Business - June 23	23.06.
Eli Lilly and Company Announces Detailed Results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Investigational Once-Weekly Insulin Efsitora Alfa	22.06.
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects	22.06.
Eli Lilly's Orforglipron Reduces Blood Sugar, Weight in Phase 3 Trial	22.06.
China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds	21.06.
Lilly expects orforglipron obesity results in third quarter	21.06.
Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone	21.06.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Eli Lilly CEO über den Kampf gegen Krebs und Fettleibigkeit, Arzneimittelpreise

Am 13. Januar 2025 um 17:30 Uhr

Anti-Adipositas: Des einen Leid ist des anderen Freud

Am 26. November 2024 um 16:45 Uhr